Form 4: Impact Biomedical CEO Acquires 500 Shares in Open Market Transaction

Impact Biomedical's CEO, Frank D. Heuszel, purchased 500 shares of common stock at $2.61 per share on November 27, 2024.

Summary

• Frank D. Heuszel, the CEO of Impact Biomedical Inc., acquired 500 shares of the company's common stock.
• The transaction occurred on November 27, 2024.
• The purchase price was $2.61 per share.
• Following the transaction, Mr. Heuszel directly owns 96,844 shares of Impact Biomedical stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a routine insider transaction. The CEO's purchase could be seen as a positive signal, but it's not a major event.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.
• The purchase increases the CEO's alignment with shareholder interests.

Industry Context

This is a routine disclosure of an insider transaction, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Insider trading disclosures are standard practice for publicly listed companies and are required by the SEC.
• The transaction is relatively small in volume compared to typical institutional trading activity.
• The purchase is not unusual for a CEO and is within the normal range of insider transactions.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased investment in the company.

Key Dates

Keywords

Impact Biomedical, Frank D. Heuszel, insider trading, share purchase, common stock, CEO, ownership